Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study-Reference-Cited by-同舟云学术

Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study

Published:2010-10 Issue:5 Volume:10 Page:379-384
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chang Julie E.,Seo Songwong,Kim Kyungmann M.,Werndli Jae E.,Bottner Wayne A.,Rodrigues Gilberto A.,Sanchez Federico A.,Saphner Thomas J.,Longo Walter L.,Kahl Brad S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Large-cell lymphoma;Friedberg,2006

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J Clin Oncol,2006

3. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update;Morrison;J Clin Oncol,2007

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma;Coiffier;N Engl J Med,2002

5. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte;Feugier;J Clin Oncol,2005

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of solid tumors;Cochrane Database of Systematic Reviews;2024-01-16

2. Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies;Frontiers in Oncology;2022-07-07

3. GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization;Cancer Cell International;2021-03-02

4. Immune checkpoint markers and anti‐CD20‐mediated NK cell activation;Journal of Leukocyte Biology;2020-12-08

5. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis;The Lancet Haematology;2020-04